The safety and tolerability of BIKTARVY®▼(bictegravir / emtricitabine / tenofovir alafenamide) is consistent between treatment-naïve and virologically suppressed adults.1 The most frequently reported adverse reactions from phase III trials involving both cohorts is summarised below.
You are now leaving www.hiv.eu and visiting a new site which is not owned or controlled by Gilead Sciences. Gilead Sciences is therefore not responsible for your interactions with the website or the information it provides.
You are now leaving www.hiv.eu and visiting a new site which is not owned or controlled by Gilead Sciences. Gilead Sciences is therefore not responsible for your interactions with the website or the information it provides.
